BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 10506630)

  • 1. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Royce ME; McGarry W; Bready B; Dakhil SR; Belt RJ; Goodwin JW; Gray R; Hoff PM; Winn R; Pazdur R
    J Clin Oncol; 1999 Oct; 17(10):3276-82. PubMed ID: 10506630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
    O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
    J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
    Kemeny N; Conti JA; Seiter K; Niedzwiecki D; Botet J; Martin D; Costa P; Wiseberg J; McCulloch W
    J Clin Oncol; 1992 May; 10(5):747-52. PubMed ID: 1569447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
    Langer CJ; Schaebler D; Sauter E; DeMaria D; Johnson C; Reilly DM; Clark J; Leighton J; Aks C; Litwin S; Ridge JA
    Head Neck; 1998 Aug; 20(5):385-91. PubMed ID: 9663665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
    Harte RJ; Matthews JC; O'Reilly SM; Tilsley DW; Osman S; Brown G; Luthra SJ; Brady F; Jones T; Price PM
    J Clin Oncol; 1999 May; 17(5):1580-8. PubMed ID: 10334547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
    Nassim MA; Rouini MR; Cripps MC; Shirazi FH; Veerasinghan S; Molepo JM; Obrocea M; Redmond D; Bates S; Fry D; Stewart DJ; Goel R
    Oncol Rep; 1998; 5(1):217-21. PubMed ID: 9458325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
    Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Lenk H; Wiener N; Boese-Landgraf J; Schalhorn A
    Semin Oncol; 1992 Apr; 19(2 Suppl 4):57-62. PubMed ID: 1553576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
    Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
    Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
    J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
    Hageboutros A; Hudes GR; Greene F; LaCreta FP; Brennan J; O'Dwyer PJ
    Invest New Drugs; 1997; 15(2):139-45. PubMed ID: 9220293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study.
    Hartmann JT; Köhne CH; Schmoll HJ; Daikeler T; Kanz L; Bokemeyer C
    Oncology; 1998; 55(4):320-5. PubMed ID: 9663421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
    Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
    J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
    Köhne-Wömpner CH; Schmoll HJ; Harstrick A; Rustum YM
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):105-25. PubMed ID: 1373004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid.
    b1p6uller J; Czejka M
    Med Oncol; 1995 Mar; 12(1):47-53. PubMed ID: 8542247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
    Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
    J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
    Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
    J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
    Whitehead RP; Benedetti JK; Abbruzzese JL; Ardalan B; Williamson S; Gaynor ER; Balcerzak SP; Macdonald JS
    Invest New Drugs; 2004 Nov; 22(4):467-73. PubMed ID: 15292717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.
    Grem JL; Jordan E; Robson ME; Binder RA; Hamilton JM; Steinberg SM; Arbuck SG; Beveridge RA; Kales AN; Miller JA
    J Clin Oncol; 1993 Sep; 11(9):1737-45. PubMed ID: 8355041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
    Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomodulation of Fluorouracil in colorectal cancer.
    Ardalan B; Luis R; Jaime M; Franceschi D
    Cancer Invest; 1998; 16(4):237-51. PubMed ID: 9589033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.